Amrita Desai, MD
Medical Oncology · Portland, ORNPI 1407144439
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by National Marrow Donor Program at 48.5% of the total. 2025 is the largest year on record at $278, more than ten times the $26 reported in 2021. That places this record below the midpoint for medical oncology clinicians in OR, where the typical reported total is $810.
Across 8 payments — averaging $57.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- National Marrow Donor Program$222
- E.r. Squibb & Sons, L.L.C.$117
- Gilead$44
- AbbVie$24
- Johnson & Johnson$24
- Pfizer$14
- plus $13 from 1 others
Across 5 payments — averaging $66,199 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$240K
- E.r. Squibb & Sons, L.L.C.$91K
- AbbVie$21
What the payments were for
- Food & beverage$43294%
- Education$266%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| National Marrow Donor Program | 1 | $222 |
| E.r. Squibb & Sons, L.L.C. | 1 | $117 |
| Gilead(2 entities) | 2 | $44 |
| AbbVie | 1 | $24 |
| Johnson & Johnson | 1 | $24 |
| Pfizer | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reblozyl$117
How this compares
$458 in reported general payments places this provider in the 40th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 18 | $1,133 |
| Acyclovir | 62 | $822 |
| Prochlorperazine Maleate | 30 | $442 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $260 |
| Ondansetron OdtOndansetron | 12 | $151 |
| Potassium Chloride | 16 | $146 |
| Allopurinol | 14 | $84 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Portland
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Tomasz BeerPortland$102K
- Alison ConlinPortland$85K
- Shivaani KummarPortland$66K
- Stacy LewisPortland$57K
- Hagen KenneckePortland$53K
- Adel KardoshPortland$51K
- Brendan CurtiPortland$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.